Disc Medicine announced the appointment of Lisa Amaya Price, MBA as Chief Human Resources Officer on January 12, 2026. Ms. Amaya Price brings over 25 years of HR and organizational leadership experience from commercial-stage biopharma and life sciences companies, including senior roles at Deciphera, LGC Group (4,000 employees worldwide), Scholar Rock and Takeda Pharmaceuticals. In her new role, she will oversee recruitment, talent development and retention initiatives to support Disc’s transition from clinical-stage research to full commercialization. As part of her inducement award, Ms. Amaya Price received an option to purchase 37,500 shares of common stock, a 25,000-share restricted stock unit (RSU) award vesting over four annual installments and a supplemental 4,000-share RSU award vesting quarterly over two years, all subject to continued service and Board approvals under Nasdaq rules.

Disc Medicine closed 2025 with multiple pipeline and organizational advances and ended the year with $791 million in cash, cash equivalents and marketable securities, providing runway into 2029. Key achievements included submission and acceptance of an NDA for bitopertin under the FDA’s accelerated approval pathway with a Commissioner’s National Priority Review Voucher, positive Phase 2 data from the RALLY-MF study of DISC-0974 in myelofibrosis-related anemia, patent issuance for DISC-0974 through 2041, and initiation of Phase 2 DISC-3405 trials in polycythemia vera and Phase 1b studies in sickle cell disease. For 2026, Disc expects an FDA decision on bitopertin for erythropoietic protoporphyria, a US launch plan contingent on approval, updated Phase 2 data for both DISC-0974 and DISC-3405 in H2 2026, an End of Phase 2 meeting with the FDA for DISC-0974, initiation of a DISC-0974 trial in inflammatory bowel disease–related anemia, and continued enrollment in the global APOLLO confirmatory study with topline results anticipated in early 2027.